1. The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies

   • Maurizio Lucchesi
   • Iacopo Sardi
   • Claudio Favre

   Review Article 24 October 2017 Pages: 1047 - 1053

2. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

   • Muhammad Masab
   • Muhammad Wasif Saif

   Review Article 19 October 2017 Pages: 1055 - 1062

   

3. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

   • Nobuaki Matsubara
   • Hirofumi Mukai
   • Christian Zurth

   Original Article Open access 11 August 2017 Pages: 1063 - 1072

   

4. Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

   • Nobuaki Matsubara
   • Hirofumi Mukai
   • Christian Zurth

   Erratum 23 October 2017 Pages: 1073 - 1077

5. Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

   • Chunze Li
   • Bei Wang
   • Sandhya Girish

   Original Article 11 October 2017 Pages: 1079 - 1090

   

6. A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin

   • Lorenzo Di Cesare Mannelli
   • Mario Maresca
   • Carla Ghelardini

   Original Article 12 October 2017 Pages: 1091 - 1103

   

7. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer

   • Naminatsu Takahara
   • Yousuke Nakai
   • Kazuhiko Koike

   Original Article 16 October 2017 Pages: 1105 - 1112

   

8. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

   • Andrés Redondo
   • Silvia Bagué
   • Javier Martin-Broto

   Original Article Open access 16 October 2017 Pages: 1113 - 1131

   

9. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study

   • Yasushi Sato
   • Masahiro Hirakawa
   • Tetsuji Takayama

   Original Article 16 October 2017 Pages: 1133 - 1139

10. The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer

    • Kevin M. Koch
    • E. Claire Dees
    • Lionel D. Lewis

    Original Article 02 November 2017 Pages: 1141 - 1146

    

11. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

    • Shang-Chiung Chen
    • Matts Kagedal
    • Chunze Li

    Original Article 17 October 2017 Pages: 1147 - 1159

    

12. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

    • Heinz-Josef Lenz
    • Philip Philip
    • Maurice Berkowitz

    Original Article 17 October 2017 Pages: 1161 - 1169

    

13. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

    • R. B. Verheijen
    • L. E. Swart
    • N. Steeghs

    Original Article Open access 19 October 2017 Pages: 1171 - 1178

    

14. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

    • Kaiyan Chen
    • Xiaoqing Yu
    • Yun Fan

    Original Article 24 October 2017 Pages: 1179 - 1187

    

15. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer

    • Satoshi Kobayashi
    • Makoto Ueno
    • Shinichi Ohkawa

    Original Article 25 October 2017 Pages: 1189 - 1196

    

16. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

    • Daisuke Sakai
    • Hyun Cheol Chung
    • Toshihiko Doi

    Original Article Open access 25 October 2017 Pages: 1197 - 1207

    

17. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

    • Martin van den Bent
    • Hui K. Gan
    • David A. Reardon

    Original Article Open access 26 October 2017 Pages: 1209 - 1217

    

18. The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer

    • Masatoshi Nomura
    • Hidekazu Takahashi
    • Tsunekazu Mizushima

    Original Article 26 October 2017 Pages: 1219 - 1226

    

19. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

    • Jan de Jong
    • Peter Hellemans
    • Daniele Ouellet

    Original Article 28 October 2017 Pages: 1227 - 1237

    

20. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

    • Kiyoshi Yoshino
    • Shoji Kamiura
    • Tadashi Kimura

    Original Article 28 October 2017 Pages: 1239 - 1247

    

21. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers

    • Nagdeep Giri
    • Lisa H. Lam
    • M. Naveed Shaik

    Original Article 30 October 2017 Pages: 1249 - 1260

    

22. Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification

    • Casey L. McAtee
    • Netta Schneller
    • Eric S. Schafer

    Short Communication 19 October 2017 Pages: 1261 - 1264

23. PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine

    • Joseph Ciccolini
    • Bruno Lacarelle
    • Gérard Milano

    Letter to the Editor 13 October 2017 Pages: 1265 - 1266